I think the problem was Twiggy Forrest's charitable funding program changed direction. That left AHZ's vaccine program in the lurch.
Getting a product to market including development involves about $1billion at least but if we got sufficient traction on the clinical results, we could have attracted a JV partner.
Neither happened.
Ann: Appendix 4C - quarterly, page-153
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.65 |
Change
-0.350(2.92%) |
Mkt cap ! $246.2M | |||
| Open | High | Low | Value | Volume |
| $11.57 | $11.81 | $11.52 | $67.41K | 5.775K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 810 | $11.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.66 | 160 | 2 |
View Market Depth
| Last trade - 13.15pm 10/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |